Equity awards for BioNTech (NASDAQ: BNTX) officer disclosed
Rhea-AI Filing Summary
BioNTech SE reported new equity awards to officer Ryan James Timothy Patrick. On May 12, 2026, he received 10,069 Performance Share Units and an option over 12,586 ordinary shares as compensation, both at a grant price of zero.
The option carries an exercise price of EUR 89.38 and may be settled in ordinary shares, ADSs, or cash at the supervisory board’s election. Both the PSUs and options vest in equal annual installments over four years starting on the first anniversary of the grant date and become exercisable four years after grant, subject to performance and service conditions. PSU performance targets are based on BioNTech’s share price relative to the Nasdaq Biotechnology Index.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Ryan James Timothy Patrick
Role
See remarks.
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Option (right to buy) | 12,586 | $0.00 | $0.00 |
| Grant/Award | Performance Share Unit | 10,069 | $0.00 | $0.00 |
Holdings After Transaction:
Option (right to buy) — 12,586 shares (Direct);
Performance Share Unit — 10,069 shares (Direct)
Footnotes (4)
- F1. The exercise price of this option is EUR 89.38. Subject to adjustment such that the trading price of an American Depositary Share ("ADS") as of an exercise date does not exceed 800% of the grant date exercise price.
- F2. The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certain performance-based and other conditions.
- F3. The option may be settled in ordinary shares, ADSs and/or cash at the election of the supervisory board.
- F4. Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.
Key Figures
Performance Share Units granted: 10,069 units
Options granted: 12,586 shares
Option exercise price: EUR 89.38 per share
+2 more
5 metrics
Performance Share Units granted
10,069 units
Grant on May 12, 2026
Options granted
12,586 shares
Option (right to buy) on May 12, 2026
Option exercise price
EUR 89.38 per share
Subject to adjustment tied to ADS trading price
Vesting schedule
4 annual installments over 4 years
Commencing on first anniversary of grant date
Expiration date
May 12, 2036
Option and PSU expiration
Key Terms
Performance Share Unit, American Depositary Share, Nasdaq Biotechnology Index, exercise price, +1 more
5 terms
Nasdaq Biotechnology Index financial
"performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index"
A stock index that tracks the performance of biotechnology companies listed on the NASDAQ stock exchange, combining many firms into a single measure of the sector’s movement. Think of it as a thermometer or basket that shows whether biotech stocks are generally rising or falling; investors use it to gauge sector health, compare individual holdings against the industry, and as the basis for funds that let you invest in the whole group at once.
exercise price financial
"The exercise price of this option is EUR 89.38."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
performance-based conditions financial
"becomes exercisable four years after the grant date, subject to certain performance-based and other conditions."
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What equity awards did BioNTech (BNTX) grant to Ryan James Timothy Patrick?
BioNTech granted Ryan James Timothy Patrick 10,069 Performance Share Units and an option over 12,586 ordinary shares. These awards are part of his compensation package and are subject to multi-year vesting schedules and performance or service conditions before they can be exercised or settled.
What is the exercise price of the new BioNTech option grant reported for BNTX?
The option granted to the BioNTech officer has an exercise price of EUR 89.38 per share. It was issued with a grant price of zero, but must be paid at this exercise price when exercised, subject to adjustment tied to the trading price of the company’s ADSs.
What performance conditions apply to the BioNTech PSUs granted in this Form 4?
The PSUs are subject to performance targets based on the market price of BioNTech’s ordinary shares relative to the Nasdaq Biotechnology Index. Vesting also requires the reporting person’s continued service through each vesting date, making both market performance and tenure key factors.
When do the BioNTech option and PSUs granted to the officer become exercisable?
Both the option and the PSUs vest in equal annual installments over four years, starting on the first anniversary of the grant date. They become exercisable four years after the grant date, assuming all specified performance-based and other service conditions have been satisfied by that time.